Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).
Brief Summary: Mesothelioma is a cancer of the thin membrane that lines the chest and abdomen. Around 2500 people in the UK are diagnosed with mesothelioma each year and the median survival is approximately 8.5 months. Exposure to asbestos is the most common cause although the cancer does not usually become apparent until 40-60 years after exposure. Anti-cancer drugs (chemotherapy) are usually given to help treat mesothelioma and sometimes lung-sparing surgery (pleurectomy decortication) is undertaken. However, it is not known if this surgery, in addition to chemotherapy, can increase survival and improve the quality of life for patients. The aim of the MARS2 study is to compare surgery - (extended) pleurectomy decortication - with no surgery with respect to overall survival, cost-effectiveness and quality of life. Patients will be followed up by phone at regular intervals for 2 years. Patients will be asked to complete and return a Quality of Life Questionnaire at these time points.

MARS 2 also includes an optional 'Information study', where consenting patients may be interviewed or have their consultations audio-recorded. The aim of the Information study is to explore how a patient makes a decision to take part in research or not, with the overall aim of improving recruitment to clinical trials.


Options:
A: Arm Label: Bevacizumab plus chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab | Arm Label: Atezolizumab plus bevacizumab plus chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab, Drug: Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy
B: Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Procedure: (Extended) pleurectomy decortication | Arm Label: no surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: (Extended) pleurectomy decortication; Assigned to Arm(s): Surgery
C: Arm Label: Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Durvalumab | Arm Label: Control Arm: Chemotherapy, then Observation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy | Arm Label: Control Arm: Ipilimumab and Nivolumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ipilimumab and Nivolumab | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance | Intervention Type: DRUG; Name: Standard Chemotherapy; Assigned to Arm(s): Control Arm: Chemotherapy, then Observation | Intervention Type: DRUG; Name: Ipilimumab and Nivolumab; Assigned to Arm(s): Control Arm: Ipilimumab and Nivolumab
D: Arm Label: Dose Escalation Cohort: Avelumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 20.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: NSCLC, Post-platinum Doublet; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: NSCLC, First Line; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: Metastatic Breast Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: GC/GEJC Progressed; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: GC/GEJC Non Progressed; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Castrate-resistant Prostate Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Adrenocortical Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Melanoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Mesothelioma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Urothelial Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Ovarian Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Renal Cell Carcinoma (First Line); Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line); Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: Ovarian Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: Urothelial Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: GC/ GEJC, Third Line; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: HNSCC; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Intervention Type: DRUG; Name: Avelumab; Assigned to Arm(s): Dose Escalation Cohort: Avelumab 1.0 mg/kg, Dose Escalation Cohort: Avelumab 10.0 mg/kg, Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly, Dose Escalation Cohort: Avelumab 20.0 mg/kg, Dose Escalation Cohort: Avelumab 3.0 mg/kg, Efficacy Expansion Cohort: GC/ GEJC, Third Line, Efficacy Expansion Cohort: HNSCC, Efficacy Expansion Cohort: Ovarian Cancer, Efficacy Expansion Cohort: Urothelial Carcinoma, Primary Expansion Cohort: GC/GEJC Non Progressed, Primary Expansion Cohort: GC/GEJC Progressed, Primary Expansion Cohort: Metastatic Breast Cancer, Primary Expansion Cohort: NSCLC, First Line, Primary Expansion Cohort: NSCLC, Post-platinum Doublet, Secondary Expansion Cohort: Adrenocortical Carcinoma, Secondary Expansion Cohort: Castrate-resistant Prostate Cancer, Secondary Expansion Cohort: Colorectal Cancer, Secondary Expansion Cohort: Melanoma, Secondary Expansion Cohort: Mesothelioma, Secondary Expansion Cohort: Ovarian Cancer, Secondary Expansion Cohort: Renal Cell Carcinoma (First Line), Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line), Secondary Expansion Cohort: Urothelial Carcinoma

Answer: B